| 24th Apr 2025 7:00 am |
RNS-R |
HUTCHMED - Data to be Presented at AACR 2025 |
| 22nd Apr 2025 7:00 am |
RNS-R |
HUTCHMED Completes Enrollment of Phase II Study |
| 7th Apr 2025 9:30 am |
RNS |
2024 Annual Report and Notice of AGM |
| 31st Mar 2025 10:30 am |
RNS |
Extraordinary General Meeting – Poll Results |
| 21st Mar 2025 10:00 am |
RNS-R |
NMPA Conditional Approval for TAZVERIK® |
| 20th Mar 2025 9:30 am |
RNS |
Retirement of Independent Non-executive Directors |
| 20th Mar 2025 7:00 am |
RNS-R |
HUTCHMED Highlights Savolitinib SAVANNAH Phase II |
| 19th Mar 2025 1:45 pm |
RNS-R |
Publication of Form 20-F |
| 19th Mar 2025 11:00 am |
RNS |
2024 Final Results and Business Updates |
| 19th Mar 2025 7:00 am |
RNS-R |
Phase II/III Study of Fruquintinib and Sintilimab |
| 14th Mar 2025 9:30 am |
RNS |
Adoption of the 2025 Long Term Incentive Plan |
| 14th Mar 2025 9:30 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 13th Mar 2025 9:30 am |
RNS |
Notice of Extraordinary General Meeting |
| 6th Mar 2025 10:00 am |
RNS-R |
Completed Enrollment of Phase II Study |
| 5th Mar 2025 10:00 am |
RNS |
Directorate Change |
| 3rd Mar 2025 7:00 am |
RNS |
Overseas Regulatory Announcement |
| 28th Feb 2025 3:00 pm |
RNS |
Overseas Regulatory Announcement |
| 19th Feb 2025 8:30 am |
RNS |
Notice of Results |
| 28th Jan 2025 9:00 am |
RNS |
Overseas Regulatory Announcement |
| 14th Jan 2025 7:00 am |
RNS-R |
Full Approval for ORPATHYS in China |
| 2nd Jan 2025 7:00 am |
RNS |
Overseas Regulatory Announcement |
| 2nd Jan 2025 7:00 am |
RNS |
US$608m Divestment of Non-Core Joint Venture |
| 31st Dec 2024 8:30 am |
RNS |
Appointment of Joint Corporate Broker |
| 30th Dec 2024 8:30 am |
RNS |
Blocklisting Six Monthly Return |
| 29th Nov 2024 8:30 am |
RNS |
Total Voting Rights |
| 20th Nov 2024 9:30 am |
RNS |
Appointment of Independent Non-executive Director |
| 31st Oct 2024 8:30 am |
RNS |
Total Voting Rights |
| 21st Oct 2024 9:30 am |
RNS |
Vesting of awards under the LTIP |
| 16th Oct 2024 7:00 am |
RNS |
SAVANNAH: clinically meaningful response rate |
| 24th Sep 2024 8:00 am |
RNS |
Japan Approval for FRUZAQLA |
| 30th Aug 2024 9:30 am |
RNS |
Total Voting Rights |
| 30th Aug 2024 7:00 am |
RNS |
Update on Fruquintinib for Gastric Cancer in China |
| 22nd Aug 2024 9:30 am |
RNS |
Standard form for notification of major holdings |
| 6th Aug 2024 10:00 am |
RNS |
LTIP and Share Option Scheme |
| 31st Jul 2024 12:00 pm |
RNS |
2024 Interim Results and Business Updates |
| 28th Jun 2024 9:30 am |
RNS |
Total Voting Rights |
| 28th Jun 2024 9:30 am |
RNS |
Blocklisting Six Monthly Return |
| 26th Jun 2024 9:30 am |
RNS |
HUTCHMED to Announce 2024 HY Financial Results |
| 24th Jun 2024 7:00 am |
RNS |
European Commission Approval for FRUZAQLA |
| 7th Jun 2024 7:00 am |
RNS |
HUTCHMED Initiates Phase I Trial of HMPL-506 |
